Imagine you are a manager at a large distribution center. Your facility is around a half-million square feet, or about the same footprint as ten football fields. Hundreds of people work there each day to fulfill orders, plus many more during the busy holiday seasons. There is ample space but also plenty of “shoulder-rubbing” with […]
Posts by Markus Cueva:
FlexSim 2021 Update 1 expands on the pre-built logic for AGV systems with four new templates. It also improves model visualization in RTX Mode, adds visual options for bottling lines using the Mass Flow Conveyor, updates the Simulation Control Bar with new features and functionality, and much more.
I didn’t expect to experience déjà vu while going in to receive my first dose of the COVID-19 vaccine. My appointment took me to the largest vaccination site in the southern end of the county. I can’t think of a better location to administer vaccines en masse—it’s right off the freeway, on Main Street’s west edge in the […]
What’s the longest you’ve ever waited to see a doctor? Hopefully, your answer won’t make us shake our heads and whistle in disbelief. This question has been asked and answered on Quora, Reddit, and across social media to varying degrees of hilarity and horror. Search “making sandwich in waiting room” on Twitter, and you’ll get […]
The United States Court of Appeals for the Federal Circuit affirmed the judgment of the District Court of Utah in favor of FlexSim Software Products, Inc. and against Simio LLC, ending the patent infringement litigation initiated more than four years ago and sustaining FlexSim’s long-held belief that Simio’s asserted patent rights were invalid.
FlexSim 2021 introduces the Mass Flow Conveyor, which will help in modeling food and bulk goods manufacturing, bottling, and more. It also includes improvements to parameters and performance measures and an Empirical Distribution tool.
“Phase 1 cancer studies, which guide dose selection for subsequent studies, are almost 3 times more prevalent than phase 3 studies and have a median study duration considerably longer than 2 years, which constitutes a major component of drug development time.” It takes a long, long time for new cancer treatments to get through the […]